Acculi Labs has raised INR 5 crore in seed funding from PirE Ventures to scale Lyfas, a smartphone-based diagnostic tool designed to bring affordable early-stage health monitoring to remote and underserved populations.
Bengaluru-based health diagnostic company Acculi Labs has secured INR 5 crore, roughly $700,000, in a seed funding round led by PirE Ventures, a Mumbai-based investment firm founded by Rupam Das in May 2017. The round marks a significant step for a startup focused on a deceptively simple mission: making home-based diagnostic care accessible to the last person at the bottom of the economic pyramid.
That mission is anchored in Lyfas, Acculi's flagship product. Lyfas turns a standard smartphone into a powerful diagnostic tool capable of early detection and continuous monitoring for asymptomatic patients. The technology works even in the most remote parts of the world where traditional lab infrastructure simply does not exist. By catching health anomalies early, Lyfas gives patients a critical window to seek medical attention before conditions become serious, expensive, and difficult to treat.
Rupam Das, who serves as both CEO and CTO of Acculi Labs, made the company's intentions clear following the announcement. "The investment will be used to bring our vision to reality," Das said. "Our R&D will work with new vigour and rigour to simplify healthcare for the needy. We will run full business operations to ensure that Lyfas becomes the need of every household, irrespective of geophysical location, as we at Acculi believe that healthcare is the need of people."
The scope of that ambition is what drew PirE Ventures to the table. Geetha Mahadevappa from PirE Ventures highlighted the versatility of the Lyfas platform as a key factor in their investment decision. "We see a lot of potential in Lyfas to transform the way we diagnose and monitor diseases today," Mahadevappa said. "The asset-light and tech-driven models of the company are easily pluggable into various setups, including OPD, telemedicine, and post-surgery care. We believe that together PirE and Acculi can redefine digital health not only for people, but for the nation."
The ability to slot into existing healthcare workflows without heavy infrastructure is what makes this kind of tool genuinely practical. In a country like India, where rural clinics often lack basic diagnostic equipment and specialist access is severely limited, a smartphone-based solution that works across outpatient departments, telemedicine platforms, and post-operative monitoring represents a meaningful shift in how care can be delivered at scale.
This seed round is not Acculi Labs' first taste of institutional backing. In September 2019, the company received an undisclosed amount of pre-seed funding from a group of angel investors alongside Startup Basket, a Bengaluru-based consultancy and services firm. Government support has also played a role in the company's development. Acculi Labs received funding under the Idea2PoC scheme, part of the Startup Karnataka policy designed to help early-stage companies bridge the gap between concept and commercialization. The startup was also recognized as one of the top startups at ELEVATE 2018, an initiative run by the Department of Information Technology and Biotechnology under the Government of Karnataka.
What sets Acculi apart in the increasingly crowded digital health space is the deliberate focus on asymptomatic and early-stage monitoring rather than reactive care. Most diagnostic tools in widespread use today are designed to confirm illness after symptoms appear. Lyfas is built to flag irregularities before a patient even knows something is wrong. That distinction matters enormously in communities where the nearest hospital could be hours away and the cost of late-stage treatment is financially devastating for families.
The challenge now is execution. Seed funding gives Acculi the runway to sharpen its technology and expand its operational footprint, but scaling a hardware-independent diagnostic platform across India's diverse healthcare landscape requires navigating regulatory hurdles, building trust with practitioners, and proving clinical reliability at scale. If the company can deliver on those fronts, the broader implications for preventive healthcare in developing economies could be substantial. Watch for partnerships with telemedicine providers and state-level health programs as the next signals of whether Lyfas can move from promising tool to essential infrastructure.
